Emerging Infectious Disease ISSN: 1080-6059

Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies¹

Anthony T. Newall

, James G. Wood, Noemie Oudin, and C. Raina MacIntyre

Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Figure 2

Sensitivity analyses of clinical outcomes as key parameters are varied. In A–C, the clinical attack rate (CAR) is displayed as a function of R0 and vaccine efficacy (VE) (A), vaccine coverage and VE (B), and the delay to vaccination (C). In D, deaths prevented per 100,000 population compared with no intervention is displayed as a function of R0.

Figure 2. Sensitivity analyses of clinical outcomes as key parameters are varied. In A–C, the clinical attack rate (CAR) is displayed as a function of R₀ and vaccine efficacy (VE) (A), vaccine coverage and VE (B), and the delay to vaccination (C). In D, deaths prevented per 100,000 population compared with no intervention is displayed as a function of R₀.

Main Article

¹This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.